- Previous Close
6.580 - Open
6.540 - Bid 6.680 x --
- Ask 6.690 x --
- Day's Range
6.520 - 6.790 - 52 Week Range
4.030 - 7.780 - Volume
2,055,000 - Avg. Volume
5,623,312 - Market Cap (intraday)
13.737B - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.310 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.79
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical development collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
www.innocarepharma.comRecent News: 9969.HK
View More
Performance Overview: 9969.HK
Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9969.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9969.HK
View MoreValuation Measures
Market Cap
13.53B
Enterprise Value
6.81B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.04
Price/Book (mrq)
1.54
Enterprise Value/Revenue
7.98
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-60.32%
Return on Assets (ttm)
-4.41%
Return on Equity (ttm)
-6.71%
Revenue (ttm)
780.73M
Net Income Avi to Common (ttm)
-470.89M
Diluted EPS (ttm)
-0.310
Balance Sheet and Cash Flow
Total Cash (mrq)
7.3B
Total Debt/Equity (mrq)
24.24%
Levered Free Cash Flow (ttm)
-959.82M
Research Analysis: 9969.HK
View MoreCompany Insights: 9969.HK
9969.HK does not have Company Insights